In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis S Uchida, Y Shimada, G Summary Vascular endothelial growth factor (VEGF) affects malignant tumours by promoting angiogenesis. The tumour-suppressor gene p53 has been thought to regulate VEGF. We investigated the effect of VEGF on oesophageal carcinoma and the connection between VEGF and p53. One hundred and nine resected oesophageal squamous cell carcinomas were examined. VEGF expression was analysed by immunohistochemical staining. Sixty-five tumours (59.6%, 65 out of 109) were classified as VEGF positive. A significant correlation was found between the VEGF expression and both the depth of invasion (P = 0.0001) and lymph node metastasis (P < 0.0001). With regard to p53, we compared the expression of VEGF with the mutation of p53, examined using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing in tumour samples obtained from 36 patients who we have reported previously. The VEGF expression was significantly correlated to p53 mutation (P = 0.0291). To evaluate the angiogenesis, microvascular density (MVD) was counted, and endothelial cells were stained immunohistochemically using anti-CD34 monoclonal antibody against 29 cases with invasion limited to the submucosal layer. The average MVD had a tendency to correlate to VEGF expression (P = 0.1626). The prognoses of patients with VEGFpositive primary tumours were significantly worse than for those with VEGF-negative primary tumours (P = 0.0077). We have assumed that VEGF contributes to aggressive characteristics in oesophageal carcinomas and that VEGF expression might be affected by p53 status.
Oesophageal cancer is one of the most lethal malignant neoplasmas in intestinal diseases. In oesophageal cancer, the penetration of the muscularis mucosa by the primary tumour contributes to an increase in lymphatic metastasis and a worsened prognosis. This is contrary to the case of gastric or colonic carcinomas in which, within the submuscularis layer, lymphatic metastasis is rare and the prognosis is not greatly affected by the penetration of the submuscularis layer.
Carcinoma cells secrete several kinds of cytokines, and their characteristics are influenced by those cytokines. Vascular endothelial growth factor (VEGF) is one of the influential cytokines identified in the media conditioned by bovine pituitary follicular cells (Ferrara et al, 1989) . Four types of human VEGF have been identified, including VEGF121 (121 amino acids), VEGF165 (165 amino acids), VEGF189 (189 amino acids) and VEGF206 (206 amino acids). All four types of VEGF are secreted in abundance by many kinds of carcinoma cells (Ferrara et al, 1992) . Around the carcinoma cells, VEGF is thought to play important roles by directly stimulating endothelial cells to proliferate and migrate, and by activating several proteinase activities that degrade surrounding matrix tissues.
Recent literature about VEGF expression in oesophageal carcinoma describes how VEGF contributes to tumour progression and affects poor prognoses through angiogenesis in oesophageal squamous cell carcinoma (Inoue et al, 1997) .
In contrast, mutations of the tumour-suppressor gene p53 trigger off tumorigenesis, and interestingly some reports show the possibility that they might be connected with angiogenesis. Mutant p53 could enhance VEGF expression induced by 12-O-tetradecanoylphorbol-13-acetate by activating protein kinase C (Kieser et al, 1994) . Other possibilities are that wild-type p53 represses VEGF transcription, but p53 mutants don't affect promoter activity, and that wild-type p53 also represses v-Src-mediated VEGF up-regulation (Mukhopadhyay et al, 1995) . Although the correlation between VEGF and p53 has been suggested in vitro, there are few reports showing it in clinical materials or in vivo (Plate et al, 1994) .
Previously, we detected mutations of p53 in 47% of oesophageal squamous cell carcinoma (Wagata et al, 1993; Shibagaki et al, 1995) and suggested that p53 plays an important role in oesophageal carcinogenesis.
In this study, we first investigated the correlation between the clinicopathological factors of oesophageal carcinoma and the expression of VEGF by immunohistocytochemistry. Secondly, we examined whether VEGF might affect the microvascular increase in oesophageal carcinoma. Finally, we evaluated whether the expression of VEGF correlated to the status of p53 genes in oesophageal carcinoma.
MATERIALS AND METHODS Clinical materials
Tissues were obtained from oesophageal cancer specimens of 109 patients who underwent oesophagectomies at our institution from June 1987 to December 1995. The operation techniques used were as previously described (Imamura et al, 1987 goat serum in PBS for 30 min at room temperature to block nonspecific antibody reaction. Sections were incubated overnight at 4°C with anti-human VEGF polyclonal antibody in PBS containing 1% bovine serum albumin. Anti-human VEGF polyclonal antibody was a kind gift from T Ishiwata of the first Department of Joint Disease and Department of Pathology, Nippon Medical School, Tokyo, Japan (Shiraishi et al, 1995) . After six rinses in PBS, sections were incubated for 40 min at room temperature with biotinylated anti-rabbit immunoglobulin G, followed by six washes with PBS, and reacted with an avidin-biotin system, using 0.03% 3,3'-diaminobenzide tetrahydrochloride for about 2 min as chromogen. Sections were counterstained with Mayer's haematoxylin and defined as positive if the membranes or cytoplasm of more than 10% of the tumour cells were stained. Negative controls, prepared by substituting normal rabbit serum for the primary antibody, resulted in no detectable staining. All slides were analysed by two investigators (SU and IS) without knowledge of the patients' clinical information.
Endothelial cells were stained to examine microvascular density with a monoclonal antibody (QB-END/10; Novocastra Laboratory, Newcastle, UK) against the endothelial marker (CD34) (Tanigawa et al, 1996) . Immunohistochemical staining was conducted in the same way as in VEGF. To evaluate microvessel quantitation, slides were scanned at low-power magnification (x 40 to x 100) to identify the areas with the highest number of vessels. In each tumour, the five areas considered to be of the highest density were selected and counted at x200 power magnification, and the averages were recorded. Vessels with thick muscular walls and vessels of a calibre larger than approximately eight red blood cells were excluded from the count. Single endothelial cells or clusters of endothelial cells, with or without a lumen, were considered to be individual vessels (Bosari et al, 1992 ).
Oesophageal carcinoma cell lines
To investigate whether oesophageal carcinoma cells express VEGF, we screened 18 oesophageal carcinoma cell lines that had been established in our laboratory (Shimada et al, 1992) We examined their mRNA expression using the Northern hybridization method.
Preparation of RNA from cell lines TRIzolTM reagent was purchased from Life Technologies. Cultured cells were lysed with TRIzolTM reagent and scraped with passing cell lysate several times through a 22-gauge needle. The cell lysate was then collected in centrifugation tubes, and the RNA of the cells was extracted according to the product's manual.
DNA probes for Northern blot analysis
The DNA probe for human VEGF165 protein was prepared as follows: 5 jg of human liver total RNA was reverse transcribed with random primers, using a commercial kit (First Strand Synthesis Kit; Pharmacia, Piscataway, NJ, USA). The resulting complementary DNA (cDNA) mixture was subjected to 30 cycles (1 min at 94°C, 1 min at 550 and 1 min at 72°C) of polymerase chain reaction (PCR) amplification using a DNA thermal cycler (Aster, Japan), Taq DNA polymerase (Toyobo, Japan) and specific VEGF primers. The following oligonucleotide primers, which were based on the human VEGF cDNA sequence, were used British Journal of Cancer (1998) 77(10) into the EcoRV site of the pBluescript SK(-) plasmid (Marchuk et al, 1991) , and the inset was confirmed by sequencing. The insert was purified and used as a probe in Northern blot analysis.
Northern blot analysis
Hybond N+ nylon membrane, rapid hybridization buffer and the Megaprime DNA labelling kit were purchased from Amersham Lifescience (UK). [kx-32P]dCTP was purchased from ICN Biomedicals (USA). Ten micrograms of mRNA were electrophoresed on a 1.0% agarose gel containing 2.2 M formaldehyde in 1 x 3-(N-morpholino)propanesulphonic acid (MOPS) buffer (20 mm MOPS, 5 mM sodium acetate, 1 mM EDTA-2Na) and then transferred to a Hybond N+ nylon membrane by capillary blotting, followed by ultraviolet (UV) cross-linkage.
Blotted membranes were prehybridized in rapid hybridization buffer at 65°C for 30 min. [a-32P]dCTP-labelled human VEGF165
cDNA was prepared using a Megaprime DNA labelling kit. Sephadex-G column was used to remove the free radioisotope. Hybridization was performed at 65°C for 2 h and then the membranes were washed twice for 10 min at room temperature in 2 x standard saline citrate (SSC) (300 mM sodium chloride, 30 mM sodium citrate) with 0. 1% sodium dodecyl sulphate (SDS). If background radioactivity was high, membranes were washed again at 65°C for 20 min in 1 x SSC with 0.1% SDS, and then at 65°C for 15 min in 0.1 x SSC with 0.1% SDS. Membranes were exposed to Fuji radiographic films at -80°C for appropriate intervals. All techniques were performed according to standard methods described previously (Sambrook et al, 1989) . Expression of mRNA was quantified using the BAS station system (Fuji photo film, Japan).
Statistical analysis
Results among VEGF, p53 mutation and clinical factors were analysed using x2 analysis and Fisher's exact test. Microvascular count was analysed using an unpaired t-test. Survival curves of the patients were calculated using the Kaplan-Meier method and statistically analysed using the generalized Wilcoxon test. Multivariate analysis was performed using the Cox proportional hazards model.
RESULTS
VEGF was mainly detected on the cytoplasms or the membranes of the carcinoma cells (Figure 1 ). Carcinoma cells seemed to stain stronger on the marginal region of the cancer nest than in the tumour centre. Few cancer nests were stained diffusely. Vascular endothelial cells beside strongly stained cancer nests were also stained. Cancer cells stained more intensely than smooth muscle. Overall, 65 (59.6%) tumours were classified as VEGF positive. Table 1 shows the correlation between VEGF expression and various factors. The VEGF-positive rate exceeded its negative rate when the tumours grew deeper than T2 level. the VEGF expression also correlated to lymph nodal metastasis. To evaluate the status of VEGF at metastatic lymph nodes, lymph node metastatic lesions were stained immunochemically with anti-VEGF antibody. Interestingly, we could not find a relationship between the result of primary lesions and that of lymph node metastatic lesions (Table  2) . Of the 109 patients, a small group had distant metastasis. When distant metastasis was detected, a tendency for a higher proportion of VEGF-positive than VEGF-negative cases was found. As a result, the VEGF-positive rate became significantly higher (P<0.0001) with stage advance.
To evaluate the vascular sprouting, the number of endothelial cells stained by anti-CD34 monoclonal antibody was counted Figure 2 ). Eleven patients out of 29 immunohistochemically stained cases were defined as VEGF positive. The average of microvascular density (MVD) in VEGF-positive patients was higher than that of VEGF-negative patients, but we could not find a significant difference between them (P = 0.1626) (Figure 3) . With regards to the 36 patients whom we had previously screened with p53 mutations using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing (Shibagaki et al, 1995) , we Survival (years) Figure 4 The relation between the influence of VEGF and survival rate.
Survival curves of the patients were calculated using the Kaplan-Meier method. Seven out of 109 patients were non-curative cases, therefore we excluded these patients in this analysis was significantly higher than in the wild-type-p53 tumours (Table 3) (P = 0.0291). The survival rates of 102 patients who received curative resection (RO) were examined. (Fifteen out of 18 stage IV patients did not have organ metastases, except for cervical lymph nodal metastases, which were resected.) Naturally, the survival rate of VEGFpositive cases was significantly lower than that of VEGF-negative cases, proportional to the clinical classification (P = 0.0077) (Figure 4 ). Multivariate analysis using Cox's proportional hazards model revealed that there was no significant correlation between the expression of VEGF and the patients' outcome (Table 4) .
In our 18 oesophageal carcinoma cell lines, we found various degrees of VEGF mRNA expression among all 18 cell lines. The ratio of VEGF mRNA expression to G3PDH varied from 0.547 to 6.45, but no correlation was found between the expression of VEGF and p53 mutations (Tanaka et al, 1996) . (Liotta et al, 1988) . Tumour angiogenesis induced by VEGF may facilitate this process by increasing tumour volume and superficial area, thus enhancing tumour celllymphatic contact at the growing margin of the tumour. It may also increase the numbers of lymphatic-haematogenous communications, allowing more intravascular micrometastasis to enter the lymphatic spaces (Blood et al, 1990) . VEGF is also known as vascular permeability factor and is thought to activate natural killer cells into connecting with endothelial cells through adhesional molecules (Melder et al, 1996) . Furthermore, VEGF has been shown to induce urokinase-type plasminogen activator (uPA), tissue-type PA (tPA) and plasminogen activator inhibitor-I (PAl-1) in vascular endothelial cells and bovine lymphatic endothelial cells (Pepper et al, 1991 (Pepper et al, , 1994 . VEGF also induces uPA receptor in vascular endothelial cells (Mandriota et al, 1995) . VEGF might facilitate lymph nodal metastasis by degrading tumour marginal extracellular matrix through uPA and the uPA receptor system as well as through matrix metalloproteinases (MMP), some of which might be activated by plasmin. These connections may facilitate the extravasation of the carcinoma cells at primary sites and may be one cause of VEGF-positive staining of primary tumours increasing lymph node metastasis. In contrast, our data showed that the expression of VEGF at metastatic lymph nodes did not depend on the expression of VEGF at primary tumours.
With regard to the regulation against the expression of VEGF, several factors, such as hypoxia, oestrogen levels and p53 mutation, were reported to induce the expression of VEGF (Schweiki et al, 1992; Garrido et al, 1993; Kieser et al, 1994; Mukhopadhyay et al, 1995) . Our results show that the mutation of p53 coexisted with the expression of VEGF in oesophageal carcinoma patients, but the detailed mechanisms determining how mutant p53 induces VEGF expression are not known.
It has been reported that increase of the microvessels around the tumour might worsen the prognosis of oesophageal carcinoma. (Tanigawa et al, 1997) . Inoue et al (1997) reported from their immunohistochemical study of vessel density using anti-factor VIII antibody that VEGF might mediate angiogenesis in oesophageal carcinoma. To investigate whether VEGF really induces microvessels around the oesophageal tumour, we examined the microvascular density by staining endothelial cells immunohistochemically, using anti-CD34 antibody. Anti-CD34 antibody is more specific than anti-factor VIII antibody and, because the average vessel counts were approximately three times higher with CD34 staining than with factor VIII staining (Tanigawa et al, 1997) , it may be controversial to evaluate vessel density using anti-factor VIII antibody. Although we could not find a significant difference in microvascular density between VEGF-positive cases and VEGF-negative cases, we found that the VEGF-positive cases tended to show a higher number of microvascular counts than VEGF-negative cases. Even if they were normal tissues, the basic number of the endothelial cells in each layer varied. In the case of carcinoma tissues, the endothelial cell count at different layers may be influenced by the variety of the basic number of them. In many cases, the structure of the muscular layer tissues invaded by the carcinoma was destroyed too severely to investigate endothelial cell numbers, so our research was limited to 29 cases whose depths of invasion were at the submucosal layer. We could not show a significant difference in endothelial cell numbers between VEGF-positive cases and VEGF-negative cases.
Finally, although there is the possibility that cancer cell lines may change their natural character, we confirmed VEGF expression in oesophageal cancer by detecting its mRNA in cell lines. Our results may indicate that the expression of VEGF is common in oesophageal cancer and well correlated with p53 status in vivo; however the same correlation was not shown in vitro. There may be the involvement of other factors. We have already examined the p53 status of these cell lines (Tanaka et al, 1995) , so we are now analysing them for direct evidence of a correlation between p53
British Journal of Cancer (1998) 
